U.S. stock futures are slightly higher this morning, as investors await economic data. Futures on the Dow Jones Industrial Average gained 12 points to 12,182, while futures on the S&P 500 index rose 1.3 points to 1,311.30. Nasdaq 100 futures climbed 6.75 points to 2,323.75.

U.S. stocks closed higher on Friday, with the Dow Jones industrial average gaining 50 points to 12,221, the Standard & Poor's 500 Index rising 4 points to 1,314 and the Nasdaq Composite Index climbing 7 points to 2,743.

Coca-Cola (KO) has more than $13 billion in cash.

The top five companies (according to market cap) are:

• Exxon Mobil (XOM): $398.3 billion
• Apple (AAPL): $309.0 billion
• Microsoft (MSFT): $237.5 billion
• General Electric (GE): $215.0 billion
• Berkshire Hathaway (BRK.A): $202.5 billion

Analyst Upgrades

• Hewlett-Packard (HPQ) to buy from neutral at UBS.
• Fluor (FLR) to overweight from neutral at JPMorgan.
• Macy's (M) to outperform from neutral at Credit Suisse.
• Canadian Solar (CSIQ), JA Solar (JASO) and HeartWare (HTWR) to buy from hold at Auriga.
• Ashford Hospitality (AHT) to outperform from market perform at FBR Capital.
• RenaissanceRe (RNR) to buy from neutral at Janney Capital.
• DCT Industrial (DCT) to market perform from underperform at Wells Fargo.
• Coeur d'Alene Mines (CDE) and Silver Standard (SSRI) to buy from hold at Deutsche Bank.
• Weatherford (WFT), Hercules (HERO), GulfMark Offshore (GLF), Tidewater (TDW) and GlaxoSmithKline (GSK) to buy from hold, and Diamond Offshore (DO) to hold from underperform, at Jefferies.
• Ritchie Bros. (RBA) to buy from neutral at BofA/Merrill.
• AstraZeneca (AZN) to buy from hold at Citigroup.

Analyst Upgrades

• Oracle (ORCL) to outperform from perform at Oppenheimer.
• Accenture (ACN) to buy from hold at Jefferies.
• Advanced Energy (AEIS) and Applied Materials (AMAT) to overweight from equal weight at Barclays.
• Spreadtrum (SPRD) to buy from hold at Auriga.
• Healthcare Realty Trust (HR) and Tortoise Energy Capital (TYY) to outperform from neutral at RW Baird.
• Global Payments (GPN) to equal weight from underweight at Morgan Stanley.
• CBS (CBS) to buy from neutral at BofA/Merrill.
• Sonic (SONC) to outperform from neutral at Cowen.

Early Friday morning, Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) announced the results of their randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes that is inadequately controlled with metformin therapy. The study showed that dapagliflozin was non-inferior compared to glipizide (sulphonylurea) and improved glycosylated hemoglobin levels (HbA1c).

In addition to these results, the study also showed that dapagliflozin plus metformin brought about "significant reductions in efficacy secondary endpoints: reduction in total body weight from baseline, compared with a weight gain on glipizide plus metformin therapy, and a reduced number of patients reporting one or more hypoglycemic events."

Tuesday morning, drugmaker Mylan (MYL) announced that the Food and Drug Administration (FDA) granted regulatory approval for a generic version of Arimidex, which is produced by AstraZeneca (AZN).

Reportedly, the FDA approved 1-milligram tablets of anastrozole, which is the active ingredient in AstraZeneca's Arimidex. Anastrozole is used to treat some breast cancer in postmenopausal women. This news follows Tueday's approval of a generic version of Arimidex that is produced by Teva Pharmaceutical (TEVA).

AstraZeneca (AZN) is in a race against time to develop new drugs as patent expiration dates are looming for some of its most profitable medicines over the next few years.

The company had hoped that motavizumab -- a medicine that is supposed to help prevent respiratory disease in infants -- would be one of the drugs to issue in a new era of profits by replacing Synagis -- a patented drug that fights the same virus. Unfortunately for AstraZeneca, that may not happen.

AstraZeneca (AZN) and Abbott Laboratories (ABT) announced this morning they received a complete response letter from the Food and Drug Administration regarding their new drug application for Certriad capsules. The FDA requested more information. The companies stated that they are currently evaluating the FDA's letter and will continue discussions with the agency to see what the next step will be with the drug. AZN and ABT will then respond to the FDA's request for further information.

Certriad is for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including the "bad" cholesterol (LDL), high triglycerides, and low "good" cholesterol (HDL). The active ingredients in Certirad are Crestor and Trilipix from ABT and AZN.

This was one of those days where many of the same concerns over sovereign debt risk and international issues were there, but the market rallied as the fears were not broadcast at every media report. Commodities saw large gains as fears about Greece were not as predominant.

Here were today's unofficial closing bell levels:

Dow 10,267.83 +168.69 (1.67%)
S&P 500 1,094.86 +19.35 (1.80%)
Nasdaq 2,214.19 +30.66 (1.40%)

Top Day Trader Alerts
Top Analyst Upgrades & Downgrades

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Abercrombie & Fitch Co. (ANF) lower Q3 results still topped expectations and sent shares higher.
• Applied Materials Inc. (AMAT) posted much better-than-expected Q4 earnings, the first profit in a year.
• AstraZeneca (AZN) received an analyst's downgrade due to concerns over its earnings prospects.
• Blackstone Group (BX) received an analyst's upgrade following the company's Q3 results.
• Blockbuster Inc. (BBI) widened its net loss in Q3 and revenue and same-stores sales declined.
• Clean Energy Fuels Corp. (CLNE) shares declined after its Q3 numbers fell short of expectations.
• Consolidated Water Co. Inc. (CWCO) earnings prospects for 2010 earned it an analyst upgrade.

Analyst upgrades:

• Keefe Bruyette upgraded Blackstone Group (BX) to outperform from market perform following the company's Q3 results and maintains an $18.50 price target on shares.
• Baird upgraded Astec (ASTE) to outperform from neutral citing relative valuation and upside from new multi-year U.S. highway funding legislation. The firm raised its target to $33 from $27.
• Goldman upgraded Abercrombie & Fitch (ANF) to conviction buy from neutral citing "significant" long-term growth drivers that include international growth. The firm raised its target to $45 from $36.
• Ariad Pharmaceuticals (ARIA) was upgraded to overweight from neutral at JPMorgan.
• Energizer (ENR) was upgraded to overweight from equal weight at Morgan Stanley.
• AstraZeneca (AZN) was upgraded to buy from hold at RBS.

"Investors considering high-yield stocks should consider financial strength; in our quantitative model, Quadrix, we assess profit margins, interest coverage, and debt levels," says Richard Moroney.

In Dow Theory Forecasts, a newsletter that has been published for over 5 decades -- he looks at two stocks that score high in this area: drug manufacturer, AstraZeneca (NYSE: AZN) and defense industry player, General Dynamics (NYSE: GD). Here, the advisor reviews the two companies.

"AstraZeneca's operating cash flow jumped 24% in the first half of 2009, allowing the company to retire $3 billion in debt since the end of 2008.

There is good news surfacing for pharmaceutical firm AstraZeneca (NYSE: AZN) this morning. Turns out a new drug produced by AZN helps reduce heart patients' chances of dying by more than 20% when compared to the standard treatment. The drug is designed to prevent blood clots in heart patients.

The study followed 18,624 patients from 2006 to 2008, with roughly half taking rival medicine Plavix and the other half taking AZN's Brilinta. The results show that patients taking Brilinta had a 4.5% chance of dying, compared to a 5.9% chance for patients on Plavix.

Stocks are up this year but not everyone is profiting. One reason is that many investors, stung by the market collapse, have been looking for safety by investing in dividend paying stocks. But Richard Moroney, editor of Dow Theory Forecasts, says that investing for yield is a flawed strategy.

Moroney, a chartered financial analyst, points out that while the S&P 1500 Index is up about 16% so far this year, investors in high-yielding stocks (with yields of 4% or more) have a year-to-date return of just 4%. And he says that stocks that do not pay dividends are up an average of 29%.

We spoke with Richard Moroney to find out why this is the case -- and what income investors should do.

In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.

Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments.

"AstraZeneca is a leading pharmaceutical firm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales.